...
首页> 外文期刊>Spine >Perioperative complications of recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge versus iliac crest bone graft for posterior cervical arthrodesis.
【24h】

Perioperative complications of recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge versus iliac crest bone graft for posterior cervical arthrodesis.

机译:重组人骨形态发生蛋白2在可吸收性胶原海绵与c顶骨移植物上进行后颈椎关节置换术的围手术期并发症。

获取原文
获取原文并翻译 | 示例
           

摘要

STUDY DESIGN: Retrospective evaluation of perioperative complications with recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge (rhBMP-2/ACS) versus iliac crest bone graft (ICBG) for instrumented posterior cervical fusion. OBJECTIVE: To determine the risk of perioperative complications using rhBMP-2/ACS for posterior cervical fusion compared with ICBG. SUMMARY OF BACKGROUND DATA: There is substantial use of rhBMP-2/ACS as a bone graft substitute for spine fusions outside the Food and Drug Administration-approved indication of anterior lumbar interbody fusion. Efficacy for inducing fusion and avoidance of iliac crest donor-site complications are frequent reasons cited for its use. Previous studies have reported use in the anterior lumbar spine, the posterior lumbar spine, and in the anterior cervical spine. Site-specific perioperative complications that have been reported, especially with use in the anterior cervical spine, confirm that safety and efficacy should be established for specific anatomic sites and clinical indications. METHODS: From July 2002 to February 2005, a consecutive series of patients who underwent instrumented posterior cervical fusion were identified. Patients received either rhBMP-2/ACS or ICBG based on the discretion of the surgeon. Patients were excluded if they had a preoperative diagnosis of trauma, tumor, or infection, or if they underwent a concomitant anterior procedure. Seventy-seven patients met the inclusion criteria. Forty-one of these patients received rhBMP-2/ACS and 36 received ICBG. Standard demographic, surgical, and perioperative complication data were collected from the medical records. RESULTS: There were no significant differences in age, gender distribution, smoking status, number of surgical levels, blood loss, operative time, or length of stay between the 2 groups. There were more posterior cervical wound complications requiring treatment in the rhBMP- 2/ACS group (6, 14.6%) versus the ICBG group (1, 2.8%), although this was not statistically significant (P = 0.113). One patient (2.8%) in the ICBG group had a wound complication at the iliac crest donor site. Additional perioperative complications were noted in 3 patients (7.3%) in the ICBG group and none in the rhBMP-2/ACS group. CONCLUSION: The higher incidence of posterior cervical wound complications in the rhBMP-2/ACS group, although not statistically significant, may be related to an inflammatory response to rhBMP-2. This potential risk must be weighed against the elimination of donor-site complications associated with ICBG harvesting, and considered in light of ultimate clinical outcome. Additional studies are needed to clarify this issue, as well as to determine optimal dosing and carrier for usage in the posterior cervical spine.
机译:研究设计:回顾性评估重组人骨形态发生蛋白2在可吸收性胶原海绵(rhBMP-2 / ACS)与顶骨移植物(ICBG)上进行颈椎后路融合术的围手术期并发症。目的:确定与ICBG相比,使用rhBMP-2 / ACS进行颈椎后路融合术的围手术期并发症风险。背景数据摘要:在美国食品和药物管理局批准的前腰椎椎间融合术的指征之外,rhBMP-2 / ACS被大量用作脊柱融合术的骨移植替代物。诱导融合的功效和避免donor的供体部位并发症是其使用的常见原因。先前的研究报道了在前腰椎,后腰椎和颈前椎中使用。已报道的特定部位围手术期并发症,尤其是在颈椎前路使用时,证实应针对特定解剖部位和临床指征确定安全性和有效性。方法:从2002年7月至2005年2月,确定了一系列接受仪器后路颈椎融合术的患者。根据外科医生的判断,患者接受了rhBMP-2 / ACS或ICBG。如果患者在术前诊断出有外伤,肿瘤或感染,或者接受了前路手术,则将其排除在外。 77名患者符合纳入标准。这些患者中有41例接受了rhBMP-2 / ACS接受治疗,其中36例接受了ICBG治疗。从医疗记录中收集标准的人口统计学,外科手术和围手术期并发症数据。结果:两组之间的年龄,性别分布,吸烟状况,手术次数,失血量,手术时间或住院时间无显着差异。与ICBG组(1,2.8%)相比,rhBMP-2 / ACS组(6,14.6%)有更多需要治疗的颈椎后路并发症,尽管这在统计学上没有统计学意义(P = 0.113)。 ICBG组中的一名患者(2.8%)在donor donor供体位点有伤口并发症。 ICBG组中有3例(7.3%)出现其他围手术期并发症,而rhBMP-2 / ACS组中无一例。结论:rhBMP-2 / ACS组颈后伤口并发症发生率较高,尽管无统计学意义,但可能与对rhBMP-2的炎症反应有关。必须权衡这种潜在风险,以消除与ICBG收获相关的供体部位并发症,并根据最终临床结果进行考虑。需要进一步的研究来阐明这个问题,并确定在颈椎后路使用的最佳剂量和载体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号